Shelley and Todd Engel. The Engel family hide caption toggle caption i The Engel family Todd Engel had operated heavy machinery, like forklifts and rubber-tire loaders, around warehouses and highways in suburban Maryland for four decades. In early 2023, Engel’s doctor put him on Ozempic, a GLP-1, for diabetes. That winter, on New Year’s Eve,
The health wave has made its impact on what could have been considered its mortal enemy: fast food. In a far cry from its old era of “supersized” menus, McDonald’s is exploring a new $8.5 billion, decade-long “McDonald’s Next” overhaul—and the fast food giant is exploring smaller and more flexible portions aimed at protein-first and
For roughly 40% of American adults living with obesity, the medical playbook has barely changed in decades: Eat less, move more, and if that fails, wait until the disease progresses far enough to justify surgery. GLP-1 drugs like Ozempic, Wegovy, and Zepbound have broken that script—but according to Robin Wenzel, head of Wells Fargo Industry
